Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
US pharma major Bristol-Myers Squibb has appointed Dr Thomas Lynch, Jr, as executive vice president and chief scientific officer, effective March 16, 2017. 9 March 2017
USA/Israel-based biotech firm BrainStorm Cell Therapeutics has appointed Ralph Kern to the positions of chief operating and chief medical officer, effective March 6, 2017. 6 March 2017
Denmark-based allergy specialist ALK-Abelló has appointed Hendrik Nolte as senior vice president of R&D for North America and International Markets, based in the USA. 3 March 2017
Investors in Ireland-incorporated Perrigo probably did not know where to turn on Monday and Tuesday amid news on the company’s management, job cuts, divestment of royalty payment rights on a multiple sclerosis drug and its publication of bleak financial guidance. 1 March 2017
Jakob Riis, executive vice president, head of North America Operations and president of Novo Nordisk Inc, has resigned, Danish diabetes care giant Novo Nordisk announced this morning. 1 March 2017
US biotech major Celgene Corp says that its president and chief operating officer (COO) Jacqualyn (Jackie) Fouse, has decided to retire from Celgene effective June 30, 2017. 24 February 2017
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Nathalie Moll as its new director general. 22 February 2017
Teijin Pharma, the core company of Japan’s Teijin Group’s healthcare business, says that its board of directors has elected Akihisa Nabeshima as its next president. 22 February 2017
While last week’s news continued to be dominated by actions of newly-installed US President Donald Trump, including the vote to approve his controversial nominee Dr Tom Price as Secretary of Health and Human Services, the pharma industry itself was also making headlines. 12 February 2017
Oxford BioTherapeutics (OBT) has added two new names to a board now boasting significant experience in developing immuno-oncology and antibody-based therapies. 9 February 2017
Erez Vigodman is stepping down from his post as chief executive of Teva Pharmaceutical Industries “by mutual agreement,” the Israeli generics giant announced late Monday. 7 February 2017
Thomas Cueni has taken up office as director general of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) on February 1, representing the interests of the research-based biopharmaceutical industry at a global level. 7 February 2017